Core binding factor acute myelogenous leukemia-2021 treatment algorithm

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Core binding factor acute myelogenous leukemia (CBF-AML), defined by t(8;21) or inv(16)/t(16;16) chromosomal abnormalities, is typically considered a good-risk subtype of AML.
• Despite favorable risk classification, significant improvements in patient outcomes are achievable through optimized therapeutic strategies and diligent disease monitoring.

Purpose of the Study:

• To highlight the importance of incorporating gemtuzumab ozogamicin into frontline therapy for CBF-AML.
• To emphasize the role of serial monitoring of measurable residual disease (MRD) using quantitative polymerase chain reaction (QPCR) for improved prognostication and treatment adaptation.

Main Methods:

• Review of current therapeutic standards for CBF-AML, including cytarabine-based regimens.
• Discussion on the integration of targeted therapies like gemtuzumab ozogamicin.
• Explanation of quantitative polymerase chain reaction (QPCR) for monitoring unique fusion transcripts and MRD.

Main Results:

• Gemtuzumab ozogamicin incorporation into frontline therapy is recommended as a standard of care.
• Cytarabine-based induction/consolidation regimens can be augmented with anthracyclines (e.g., 3+7 regimen) or fludarabine.
• Serial QPCR monitoring of fusion transcripts enables effective MRD clearance assessment, aiding prognostication.

Conclusions:

• Optimizing treatment strategies, including the use of gemtuzumab ozogamicin and anthracyclines or fludarabine, can enhance outcomes in CBF-AML.
• Quantitative polymerase chain reaction (QPCR) is a crucial tool for monitoring MRD, allowing for personalized treatment adjustments and improved patient prognoses.